17th week of 2009 patent applcation highlights part 47 |
Patent application number | Title | Published |
20090105164 | SUBSTITUTED INDOLE-O-GLUCOSIDES - Substituted indole-O-glucosides, compositions containing them, and methods of using them, for example for the treatment of diabetes and Syndrome X are disclosed. | 2009-04-23 |
20090105165 | SUBSTITUTED BENZIMIDAZOLE-, BENZTRIAZOLE-, AND BENZIMIDAZOLONE-O-GLUCOSIDES - This invention relates to substituted benzimidazole-O-glucosides, benztriazole-O-glucosides, and benzimidazolone-O-glucosides, compositions containing them, and methods of using them, for example, for the treatment or prophylaxis of diabetes and Syndrome X. | 2009-04-23 |
20090105166 | Novel lapachone compounds and methods of use thereof - The present invention provides novel tricyclic spiro-oxathiine naphthoquinone derivatives, a synthetic method for making the derivatives, and the use of the derivatives to induce cell death and/or to inhibit proliferation of cancer or precancerous cells. The naphthoquinone derivatives of the present invention are related to the compound known as β-lapachone (3,4-dihydro-2,2-dimethyl-2H-naphtho(1,2-b)pyran-5,6-dione). | 2009-04-23 |
20090105167 | Predicting responsiveness to cancer therapeutics - The invention provides for compositions and methods for predicting an individual's responsitivity to cancer treatments and methods of treating cancer. In certain embodiments, the invention provides compositions and methods for predicting an individual's responsitivity to chemotherapeutics, including salvage agents, to treat cancers such as ovarian cancer. The invention also provides reagents, such as DNA microarrays, software and computer systems useful for personalizing cancer treatments, and provides methods of conducting a diagnostic business for personalizing cancer treatments. | 2009-04-23 |
20090105168 | Use Of HDAC And/Or DNMT Inhibitors For Treatment Of Ischemic Injury - The present invention provides methods of ameliorating or reducing the extent of ischemic injury, reperfusion injury, and myocardial infarction, by administering an inhibitor of histone deacetylase enzyme (HDAC) or an inhibitor of DNA methyltransferase enzyme (DNMT). | 2009-04-23 |
20090105169 | ALLELE-SPECIFIC SILENCING OF DISEASE GENES - The present invention is directed to small interfering RNA molecules (siRNA) targeted against an allele of interest, and methods of using these siRNA molecules. | 2009-04-23 |
20090105170 | Multiple Heat Shock Elements - A DNA molecule is provided which comprises at least 2 consensus sequences, each consensus sequence consisting of 3 pentameric units, said pentameric units having a sequence XGAAY or an inverse sequence Y′TTCX′, X being selected from the group consisting of A, T, G, and C, and Y of at least one, preferably two, still preferred all three, of said 3 pentameric units of at least one consensus sequence being selected from the group consisting of A, T, and C, the Y of the remaining pentameric units of said at least one consensus sequence being selected from the group consisting of A, T, G, and C, whereby in the case that said DNA molecule comprises more than 6 consensus sequences, Y of all pentameric units is selected from the group consisting of A, T, G, and C. | 2009-04-23 |
20090105171 | Methods for Regenerating and Repairing Damaged Tissues Using Adrenomedullin - [Problems to be Solved] An objective of the present invention is to provide methods for regenerating or repairing damaged tissues using adrenomedullin. Another objective is to provide pharmaceutical agents that comprise adrenomedullin as an active ingredient for regenerating or repairing damaged tissues. | 2009-04-23 |
20090105172 | Stabilized Aptamers to PSMA and Their Use as Prostate Cancer Therapeutics - The present invention provides stabilized, high affinity nucleic acid ligands to PSMA. Methods for the identification and preparation of novel, stable, high affinity ligands to PSMA using the SELEX™ method with 2′-O-methyl substituted nucleic acids, and cell surface SELEX™ are described herein. Also included are methods and compositions for the treatment and diagnosis of disease characterized by PSMA expression, using the described nucleic acid ligands. | 2009-04-23 |
20090105173 | Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA - The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a human p53 gene. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from acute renal failure or other kidney diseases comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient. | 2009-04-23 |
20090105174 | NUCLEIC ACIDS HYBRIDIZABLE TO MICRO RNA AND PRECURSORS THEREOF - Methods and compositions relating to nucleic acids targeting certain miRNA molecules are disclosed. The nucleic acids are useful in methods of increasing nuclear concentration of FKHR protein, decreasing cell viability, and treating cancer. | 2009-04-23 |
20090105175 | Methods and Compositions for the Treatment of Eye Disorders with Increased Intraocular Pressure - The present invention relates to methods and compositions that decrease intraocular pressure (IOP) of the eye. The compositions of the invention comprise short interfering nucleic acid molecules (siNA) including, but not limited to, siRNA that decrease expression of genes associated with production or drainage of intraocular fluid. The compositions of the invention can be used in the preparation of a medicament for the treatment of an eye conditions displaying increased IOP such as glaucoma, infection, inflammation, uveitis, and diabetic retinopathy. The methods of the invention comprise the administration to a patient in need thereof an effective amount of one or more siNAs of the invention. | 2009-04-23 |
20090105176 | Methods and Compositions for the Treatment of Eye Disorders with Increased Intraocular Pressure - The present invention relates to methods and compositions that decrease intraocular pressure (IOP) of the eye. The compositions of the invention comprise short interfering nucleic acid molecules (siNA) including, but not limited to, siRNA that decrease expression of genes associated with production or drainage of intraocular fluid. The compositions of the invention can be used in the preparation of a medicament for the treatment of an eye conditions displaying increased IOP such as glaucoma, infection, inflammation, uveitis, and diabetic retinopathy. The methods of the invention comprise the administration to a patient in need thereof an effective amount of one or more siNAs of the invention. | 2009-04-23 |
20090105177 | MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 1 EXPRESSION - Compounds, compositions and methods are provided for modulating the expression of diacylglycerol acyltransferase 1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding diacylglycerol acyltransferase 1. Methods of using these compounds for modulation of diacylglycerol acyltransferase 1 expression and for diagnosis and treatment of disease associated with expression of diacylglycerol acyltransferase 1, such as obesity and obesity-related conditions, are provided. | 2009-04-23 |
20090105178 | RNA INTERFERENCE MEDIATED INHIBITION OF PLATELET-DERIVED ENDOTHELIAL CELL GROWTH FACTOR (ECGF1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) - This invention relates to compounds, compositions, and methods useful for modulating platelet-derived endothelial cell growth factor and/or receptor (ECGF1 and/or ECGF1r) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of ECGF1 and/or ECGF1r gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of ECGF1 and/or ECGF1r genes. | 2009-04-23 |
20090105179 | DRUG CARRIERS - Compositions that can include a cationic polymeric carrier, targeting agent, and therapeutic agent are disclosed herein. The therapeutic agent may have a therapeutic activity such as inhibiting fibrosis within a target organ or tissue or inhibiting the growth of a cancer cell. | 2009-04-23 |
20090105180 | Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases - The present invention relates to methods and compositions for treatment of cardiovascular and peripheral vascular diseases using ex vivo and in vivo gene delivery technologies. One aspect of the present invention relates to a method for treating a vascular disease by introducing a DNA sequence encoding a TM protein or its variant into a segment of a blood vessel ex vivo using a gutless adenovirus vector. Another aspect of the present invention is to provide a gutless adenovirus vector carrying a transgene, such as a gene encoding TM protein or its variant. | 2009-04-23 |
20090105181 | Modulation of sodium channels by nicotinamide adenine dinucleotide - The present invention relates to the use of oxidized nicotinamide adenine dinucleotide (NAD | 2009-04-23 |
20090105182 | RNAi-MEDIATED INHIBITION OF STROMAL CELL-DERIVED FACTOR 1-RELATED TARGETS FOR TREATMENT OF NEOVASCULARIZATION-RELATED CONDITIONS - RNA interference is provided for inhibition of stromal cell-derived factor 1 (SDF1)-related targets in pathologic neovascularization-related conditions, including those cellular changes resulting from the signal transduction activity of the SDF1 targets that lead directly or indirectly to ocular neovascularization, abnormal angiogenesis, retinal vascular permeability, retinal edema, diabetic retinopathy particularly proliferative diabetic retinopathy, diabetic macular edema, exudative age-related macular degeneration, sequela associated with retinal ischemia, and posterior segment neovascularization, for example. | 2009-04-23 |
20090105183 | Pharmaceutical composition containing decoy and method of using the same - A pharmaceutical composition for performing treatment against a skin disease, the pharmaceutical composition comprising at least one decoy and a pharmaceutically acceptable carrier. The at least one decoy may be selected from the group consisting of an NF-κB decoy, a STAT-1 decoy, a GATA-3 decoy, a STAT-6 decoy, an AP-1 decoy and an Ets decoy. The at least one decoy may be an oligonucleotide including at least two decoys bonded to each other, the at least two decoys being selected from the group consisting of an NF-κB decoy, a STAT-1 decoy, a GATA-3 decoy, a STAT-6 decoy, an AP-1 decoy and an Ets decoy. The skin disease may be atopic dermatitis, psoriasis vulgaris, contact dermatitis, keloid, bedsore, ulcerative colitis, or Crohn's disease. | 2009-04-23 |
20090105184 | POSITRON EMISSION TOMOGRAPHY PROBES FOR IMAGING IMMUNE ACTIVATION AND SELECTED CANCERS - Compounds for use as PET probes and methods for synthesizing and using these, comprising [ | 2009-04-23 |
20090105185 | Nucleosides with anti-hepatitis B Virus activity - A method for the treatment of a host, and in particular, a human, infected with hepatitis B virus (HBV) is provided that includes administering an effective amount of a β-L-nucleotide, optionally in combination therapy with other drugs for the treatment of HBV or human immuno-deficiency virus (HIV). | 2009-04-23 |
20090105186 | Beta-L-N4-Hydroxycytosine Deoxynucleosides and their use as Pharmaceutical Agents in the Prophylaxis or Therapy of Viral Diseases - The invention relates to β-L-N4-hydroxycytosine nucleo-sides, pharmaceutical agents comprising same, and to the use of said β-L-N4-hydroxycytosine nucleosides and pharmaceutical agents in the prophylaxis or therapy of an infection caused by hepatitis B virus (HBV) or human immunodeficiency virus (HIV). The invention also relates to a method for the preparation of said β-L-nucleoside analogs. | 2009-04-23 |
20090105187 | METHODS OF TREATING LENTIVIRUS INFECTION - The present invention provides methods of identifying agents that reduce a level of active APOBEC3C in a cell. The present invention provides agents that reduce a level of active APOBEC3C in a cell; and compositions comprising the agents. The present invention further provides methods of reducing the mutation rate of a lentivirus in a cell; and methods of reducing the emergence of drug-resistant strains of lentivirus. The present invention further provides methods for treating lentivirus infections. | 2009-04-23 |
20090105188 | Compositions and Methods for Treating Necrotizing Enterocolitis - The present invention relates to a method for treating or preventing necrotizing enterocolitis (NEC) in a human neonate in need thereof, comprising administering to the neonate a pharmaceutically effective amount of a composition comprising a poly(ADP-ribose) synthetase/polymerase (PARP) inhibitor. Also contemplated herein is an infant food or treatment composition comprising a PARP inhibitor in an amount that is 5 to 500 times greater than a daily recommended intake dosage for the PARP inhibitor. | 2009-04-23 |
20090105189 | METHODS AND COMPOSITIONS FOR AMELIORATING OR INHIBITING DECLINE IN MEMORY OR INTELLIGENCE OR IMPROVING SAME - The present invention is directed to methods and compositions for treating and ameliorating AAMI, hippocampal dysfunction, memory disorders, and brain damage, comprising a composition comprising uridine, an acyl derivative thereof, or a uridine phosphate. | 2009-04-23 |
20090105190 | Method for Producing Fucoidan, Fucoidan, and Fucoidan-Containing Composition - The present invention provides a method for producing high molecular-weight fucoidan, which is expected to be promising as a cosmetic composition or an agent in the field of dermatology, and a high molecular-weight fucoidan-containing composition. | 2009-04-23 |
20090105191 | Pharmaceutical and Dermatocosmetic Compositions Comprising Extract of Durio Zibenthinus - The present invention relates to dermatocosmetic and pharmaceutical compositions comprising compounds obtained from | 2009-04-23 |
20090105192 | GLYCOSAMINOGLYCANS DERIVED FROM K5 POLYSACCHARIDE HAVING HIGH ANTICOAGULANT AND ANTITHROMBOTIC ACTIVITIES AND PROCESS FOR THEIR PREPARATION - Glycosaminoglycans derived from K5 polysaccharide having high anticoagulant and antithrombotic activity and useful for the control of coagulation and as antithrombotic agents are obtained starting from an optionally purified K5 polysaccharide by a process comprising the steps of N-deacetylation/N-sulfation, C5 epimerization, O-oversulfation, selective O-desulfation, 6-O-sulfation, N-sulfation, and optional depolymerization, in which said epimerization is performed with the use of the enzyme glucoronosyl C5 epimerase in solution or in immobilized form in the presence of divalent cations. New, particularly interesting antithrombin compounds are obtained by controlling the reaction time in the selective O-desulfation step and submitting the product obtained at the end of the final N-sulfation step to depolymerization. | 2009-04-23 |
20090105193 | CROSSLINKED COMPOUNDS AND METHODS OF MAKING AND USING THEREOF - Described herein are crosslinked compounds useful in numerous treatments. Described herein are methods of making crosslinked compounds via (1) the oxidative coupling of two or more thiol compounds or (2) by the reaction between at least one thiol compound with at least one thiol-reactive compound. | 2009-04-23 |
20090105194 | PROCESS FOR THE PRODUCTION OF A LOW MOLECULAR WEIGHT HEPARIN - The invention provides a process for the production of a very low molecular weight heparin (VLMWH) composition having a VLMWH content, relative to total heparin content, of at least 10% wt, said process comprising chromatographically or chemically or by filtration reducing the relative proportion of heparin having a molecular weight above 8000 Da in a heparin composition extracted from a non-mammalian, vascularised marine animal. | 2009-04-23 |
20090105195 | COMPOSITION COMPRISING MICROBICIDAL ACTIVE INGREDIENTS - An antimicrobial composition having a broad-spectrum activity against microorganisms is provided. The antimicrobial composition includes about 0.1 to about 10 percent by weight of a polyurethane polymer of total weight of the antimicrobial composition. The polyurethane polymer is selected from the group consisting of polyolprepolymer and β-Cyclodextrin-polyurethane polymer. The antimicrobial composition further includes about 0.01 to about 5 percent by weight of at least one antiseptic agent of the total weight of the antimicrobial composition. Furthermore, the antimicrobial composition includes at least one microbicidal agent. In addition, the antimicrobial composition includes a pharmaceutically acceptable excipient system. | 2009-04-23 |
20090105196 | USE OF CREATINE COMPOUNDS TO TREAT DERMATITIS - Creatine compounds for the treatment of dermatitis are described. | 2009-04-23 |
20090105197 | Use of Sodium Channel Blocking Compounds and Aspirin in Manufacturing Drugs for Producing Analgesia Synergistically in Mammals - This invention relates to the use of combinations of a sodium channel blocking compound that binds to an SSI or SS2 site of extracellular region of a sodium channel alpha subunit, and aspirin in manufacturing drugs for producing synergistically analgesic effect in mammals. Pharmaceutical compositions based upon this invention can enhance analgesic effect and reduce dosage of aspirin, therefore side effects and adverse reactions are decreased accordingly. | 2009-04-23 |
20090105198 | NOVEL ESTROGENIC COMPOUNDS - Novel estrogenic compounds of Formula I are provided. | 2009-04-23 |
20090105199 | OLIGOMERS OF CHOLESTEROL, CHOLESTEROL SULPHATE AND CHOLESTEROL ESTERS AND ALSO DRUGS CONTAINING THESE - The invention relates to new substances which are derived from cholesterol, cholesterol sulphate and cholesterol esters of a natural, semi-synthetic or synthetic origin in that they represent oligomers with a specific type of cross-linkage of the starting substances based on cholesterol. | 2009-04-23 |
20090105200 | Combination therapy - The invention provides a combination therapy for treating cancer and other neoplasms including romidepsin and a proteasome inhibitor. When administered together, romidepsin and a proteasome inhibitor (e.g., bortezomib) interact synergistically to selectively kill malignant cells at low (nanomolar) concentrations. The effect is particularly pronounced in malignant hematological cells (e.g., leukemia, lymphoma, multiple myeloma). The combination has also been found useful in treating bortezomib-resistant cancers and steroid-resistant cancers. The invention provides methods of killing malignant cells in vitro and in vivo. Pharmaceutical compositions, preparations, and kits including romidepsin and a proteasome inhibitor are also provided. | 2009-04-23 |
20090105201 | Pulmonary Pharmaceutical Formulations - The present invention provides improved pharmaceutical formulations for pulmonary delivery having improved chemical and physical stability of the therapeutic, prophylactic or diagnostic agent as compared to formulations known in the art. The improved pharmaceutical formulations of the invention for administration to the respiratory system of a patient for the treatment of a variety of disease conditions comprise a mass of biocompatible particles comprising an active agent, and a hydrogenated starch hydrosylate (HSH). The improvement over the prior art comprises the presence of HSH in the pharmaceutical formulation. The invention further relates to a method of treating diseases comprising administering the pharmaceutical formulations of the present invention to the respiratory system of a patient in need of treatment. | 2009-04-23 |
20090105202 | Androsterone Derivatives and Method of Use thereof - The disclosure provides androsterone derivatives. The derivatives of the disclosure are useful in the treatment of androgen- and estrogen-associated diseases and disorders, including breast cancer. | 2009-04-23 |
20090105203 | COMPOUNDS FOR TREATING VIRAL INFECTIONS - The invention relates to compounds, pharmaceutical compositions and methods useful for treating viral infection. | 2009-04-23 |
20090105204 | Therapeutic Uses for Aminosterol Compounds - A pharmaceutical composition includes, as an active ingredient, a compound according to formula 1436 as shown in FIG. | 2009-04-23 |
20090105205 | METHODS OF TREATING DISEASE STATES USING ANTIANGIOGENIC AGENTS - Compositions and methods for treating mammalian diseases or conditions characterized by undesirable angiogenesis by administering an effective amount of a compound of the formulae: | 2009-04-23 |
20090105206 | Copper Melphalan And Copper Tegafur As Anti-Tumor Agents - The present invention relates to the use of copper compounds of general formula Cu(L) | 2009-04-23 |
20090105207 | Copper (1) Complex - Copper (I) chloride complex of pyrazinic acid is prepared, characterized by elemental analysis, IR, UV-visible spectra and its crystal structure determined by single crystal diffraction methods. This compound is found to exhibit a very positive influence as a drug, in a pharmaceutical acceptable composition for different incurable diseases, e.g. myopathy or weakness of muscles in general, infertility, and certain genetically causes disorders in mammals. These products were found to improve symptoms of myopathy, male infertility, fatigue and weakness of muscles for different reasons, and certain genetically causes disorders in mammals. It also enhanced regeneration of tissue affected by skin burns, scars, improved alopecia, decreased blood lipids and helped in loss of weight in obese patients. The observed wide scope of activities probably due to stem cell stimulation, enhancement the immune system and role of copper dependent enzyme activity. | 2009-04-23 |
20090105208 | Substituted Piperazines as CB1 Antagonists - Compounds of Formula (I): | 2009-04-23 |
20090105209 | BTK protein kinase inhibitors - This application discloses pyridine and pyrimidine compounds according to formula I wherein R | 2009-04-23 |
20090105210 | Bicyclic Pyrimidines as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes - The present invention is directed to novel substituted bicyclic pyrimidines which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved. | 2009-04-23 |
20090105211 | INHIBITORS OF HEDGEHOG PATHWAY - The present invention is directed to a compound of Formula I | 2009-04-23 |
20090105212 | NOVEL ADENINE COMPOUND - A novel adenine compound represented by the formula (1): | 2009-04-23 |
20090105213 | Lactam compounds useful as protein kinase inhibitors - The present invention provides novel compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases. | 2009-04-23 |
20090105214 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes - Compounds of formula (I), wherein R | 2009-04-23 |
20090105215 | Heterocyclic compounds, methods for the preparation thereof, and uses thereof - The compounds of the present invention are of formula I: | 2009-04-23 |
20090105216 | 3- (AMINOMETHYLIDEN) 2-INDOLINONE DERIVATES AND THEIR USE AS CELL PROLIFERATION INHIBITORS - The present invention encompasses compounds of general formula (1) wherein R | 2009-04-23 |
20090105217 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS - Novel oxadiazole derivatives of formula (I) having pharmacological activity, processes for their preparation, compositions containing them and their use in the treatment of neurological, psychiatric disorders and gastrointestinal disorders through modulation of the nicotinic α7 receptor. | 2009-04-23 |
20090105218 | CRTH2 Receptor Ligands For Therapeutic Use - Compounds of formula (I) are useful in the treatment of disease responsive to modulation of CRTH2 receptor activity, wherein: A represents a carboxyl group —COOH, or a carboxyl bioisostere; L1 is a bond, —CH | 2009-04-23 |
20090105219 | Spirolactam Tricyclic CGRP Receptor Antagonists - Compounds of formula I: | 2009-04-23 |
20090105220 | PROCESS FOR THE PREPARATION OF NONPEPTIDE SUBSTITUTED SPIROBENZOAZEPINE DERIVATIVES - Novel spirobenzoazepine compounds, novel processes for the preparation of nonpeptide substituted spirobenzoazepine derivatives, and novel processes for the preparation of intermediates in the preparation of such derivatives. Novel intermediates in the preparation of nonpeptide substituted spirobenzoazepine derivatives. | 2009-04-23 |
20090105221 | MUSCARINIC RECEPTOR ANTAGONISTS - This present invention generally relates to muscarinic receptor antagonists of Formula (I), which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the prepration of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and the methods for treating diseases mediated through muscarinic receptors. | 2009-04-23 |
20090105222 | PREVENTION AND TREATMENT OF FUNCTIONAL SOMATIC DISORDERS, INCLUDING STRESS-RELATED DISORDERS - Methods for the prevention or treatment of stress-related disorders by administering a therapeutically effective amount of a dual serotonin/norepinephrine reuptake inhibitor to an individual under stress are described. A triple monoamine reuptake inhibitor for serotonin/noradrenaline/dopamine may also be administered to an individual at risk for a stress-related disorder. In a preferred embodiment the compound is milnacipran and is prophylactically administered at an effective amount to delay or prevent stress-related disorders in an individual at risk. | 2009-04-23 |
20090105223 | Compound Having Activity Of Blocking NMDA Receptor Channel, and Pharmaceutical Agent Using The Same - To provide a novel compound having NMDA receptor channel blocking activity, and also a pharmaceutical agent comprising the compound. | 2009-04-23 |
20090105224 | Tetrahydrobenzazepines and their use in the modulation of the dopamine d3 receptor - The invention relates to tetrahydrobenzazepines of the general formula I | 2009-04-23 |
20090105225 | 2-Substituted 4-Benzylphthalazinone Derivatives as Histamine H1 and H3 Antagonists - The present invention relates to compounds of formula (I), | 2009-04-23 |
20090105226 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS - The present invention relates to novel benzazepine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders. | 2009-04-23 |
20090105227 | Thienopyrroles As Antiviral Agents - The present invention relates to tetracyclic thienopyrrole compounds of formula (I), wherein Ar, A, D1, D2, W, X, Y and Z are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C virus. | 2009-04-23 |
20090105228 | Heterocyclic benzodiazepine cgrp receptor antagonists - Compounds of formula I: | 2009-04-23 |
20090105229 | PURINE DERIVATIVES AS KINASE INHIBITORS - The present invention provides kinase inhibitors of Formula I. | 2009-04-23 |
20090105230 | Anti-inflammatory medicaments - Novel compounds and methods of using those compounds for the treatment of inflammatory conditions are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein comprises the step of contacting the kinase protein with the novel compounds. | 2009-04-23 |
20090105231 | AMIDE DERIVATIVES AS ROCK INHIBITORS - This invention relates to novel amide derivatives and salts thereof. More particularly, it relates to novel amide derivatives and salts thereof which act as a ROCK inhibitor, to a pharmaceutical composition comprising the same and to a method of using the same therapeutically in the treatment and/or prevention of ROCK-related disease. | 2009-04-23 |
20090105232 | CYCLOHEXYL OR PIPERIDINYL CARBOXAMIDE ANTIBIOTIC DERIVATIVES - The invention relates to antibiotic cyclohexyl or piperidinyl carboximide derivatives of formula (I) | 2009-04-23 |
20090105233 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS - The invention relates in part to molecules having certain biological activities that include, but are not limited to, inhibiting cell proliferation, modulating protein kinase activity and modulating polymerase activity. Molecules of the invention can modulate casein kinase (CK) activity and/or poly(ADP-ribose)polymerase (PARP) activity. The invention also relates in part to methods for using such molecules. | 2009-04-23 |
20090105234 | EP4 Receptor Agonist, Compositions and Methods Thereof - This invention relates to potent selective agonists of the EP | 2009-04-23 |
20090105235 | INSECTICIDAL COMPOSITIONS WITH IMPROVED EFFECT - The present invention relates to increasing the activity of crop protection compositions comprising inhibitors of the nicotinic acetylcholine receptor (for example neonicotinoids) through the addition of ammonium salts and/or phosphonium salts or through the addition of ammonium or phosphonium salts and penetrants, to the corresponding compositions, to processes for preparing them and to their use in crop protection. | 2009-04-23 |
20090105236 | NEW PHARMACEUTICALLY-ACTIVE COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES - The present invention relates to the use of the compounds of general formula | 2009-04-23 |
20090105237 | Cooling compounds - A method of conferring a cooling effect on the skin or mucous membranes by applying thereto at least one compound of the Formula I: | 2009-04-23 |
20090105238 | Compounds and Relative use for the Control of Phytopathogens - Amphoteric compounds are described, having a zwitterionic structure of the betainic type having general formula (I) | 2009-04-23 |
20090105239 | 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE - The invention provides compounds of formula wherein R | 2009-04-23 |
20090105240 | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same - The present disclosure relates to methods for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome and acute myelogenous leukemia. The present disclosure further relates to compounds that can be used for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome and acute myelogenous leukemia. The present disclosure also relates to methods for identifying compounds that can be used for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome. | 2009-04-23 |
20090105241 | THIO-SUBSTITUTED TRICYCLIC AND BICYCLIC AROMATIC METHANESULFINYL DERIVATIVES - The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions of compounds of Formula (A): | 2009-04-23 |
20090105242 | Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases - Novel triazolopyridine compounds are disclosed that have a formula represented by the following: | 2009-04-23 |
20090105243 | Pyrrolo-Triazine Aniline Compounds Useful As Kinase Inhibitors - Compounds having the formula (I), | 2009-04-23 |
20090105244 | THIENOPYRIDINES AS ALLOSTERIC POTENTIATORS OF THE M4 MUSCARINIC RECEPTOR - The present invention relates to selective allosteric potentiators of the Formula (I): | 2009-04-23 |
20090105245 | METHODS FOR TREATING MACULAR EDEMA AND OCULAR ANGIOGENESIS USING AN ANTI-INFLAMMATORY AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR - The present invention provides methods for inhibiting increased vascular permeability and/or pathologic ocular angiogenesis via administration of a combination of one or more molecules that potently inhibit select receptor tyrosine kinases (RTKs) or vascular endothelial growth factor (VEGF) and one or more anti-inflammatory agents. | 2009-04-23 |
20090105246 | Sirtuin modulating compounds - Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent. | 2009-04-23 |
20090105247 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS - A compound of formula (I), a pharmaceutically acceptable salt, or hydrate thereof, and a method of preparing the same. A method of treating or preventing a physiological disorder caused by abnormal protein tyrosine kinase activity in a mammal comprising administering to said mammal a pharmaceutical composition comprising a compound of formula (I). | 2009-04-23 |
20090105248 | 3-MONOSUBSTITUTED TROPANE DERIVATIVES AS NOCICEPTIN RECEPTOR LIGANDS - Compounds of the formula | 2009-04-23 |
20090105249 | 4-phenylsulfonamidopiperidines as calcium channel blockers -
The invention relates to piperidinyl compounds of Formula (I): or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein R | 2009-04-23 |
20090105250 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS - The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, FGFR3, PDGFRβ and b-Raf kinases. | 2009-04-23 |
20090105251 | Renin inhibitors - Compounds, pharmaceutical compositions, kits and methods are provided for use with renin that comprise a compound selected from the group consisting of: | 2009-04-23 |
20090105252 | Pyrimidine Derivatives and Their Use in Therapy as well as the Use of Pyrimidine Derivatives in the Manufacture of a Medicament for Prevention and/or Treatment of Alzheimer's Disease - Compounds of formula I | 2009-04-23 |
20090105253 | Triazole Derivative and Use Thereof - The present invention relates to a thrombin receptor antagonist containing a compound represented by the formula (I) | 2009-04-23 |
20090105254 | VHR PROTEIN TYROSINE PHOSPHATASE INHIBITORS, COMPOSITIONS AND METHODS OF USE - Disclosed herein are | 2009-04-23 |
20090105255 | GLUCOKINASE ACTIVATORS - Compounds of the following formula are provided for use with glucokinase: | 2009-04-23 |
20090105256 | PRODRUGS OF ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF - Prodrugs of ion channeling modulating compounds, including, for example, prodrugs of the ion channel modulating compound of the following formula: are described herein, as well as methods of making and using such prodrugs and pharmaceutical compositions containing such prodrugs. | 2009-04-23 |
20090105257 | AMINOPHENYLCYCLOPROPYL CARBOXYLIC ACIDS AND DERIVATIVES AS AGONISTS TO GPR40 - The present invention relates generally to novel therapeutic compounds and more particularly to novel compounds, their use as GPR40 agonists, processes for their manufacture, and intermediates useful in their preparation. | 2009-04-23 |
20090105258 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME - This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salt thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRRPV1) antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, and heart disease. | 2009-04-23 |
20090105259 | Acyclic 1,4-Diamines and Uses Thereof - This invention relates to novel compounds useful in the treatment of diseases associated with TRPV4 channel receptor. More specifically, this invention relates to certain acyclic diamines, which are agonists of TRPV4 channel receptors. | 2009-04-23 |
20090105260 | Molecules to Enhance Percutaneous Delivery and Methods for Discovery Therefor - An IR spectroscopic technique provides methods for measuring the irritation potential of a formulation and to assess the ability of molecules to enhance the permeability of substances into and through skin using samples comprising stratum corneum. Molecules are screened for their performance as chemical penetration enhancers using a unique in silico procedure that may be applied iteratively in an attempt to generate molecules showing successively higher performance. Both the irritation potential and the ability of the molecule to enhance penetration are considered in the in silico approach. The invention provides specific molecules that may be used in topical or transdermal formulations to improve the delivery of actives. The structures of compounds of the invention include: Formulas (I), (II), (III), (IV), (V), (IV) and analogs thereof. | 2009-04-23 |
20090105261 | Novel substituted pyrazolo[1,5<I>A</I>]-1,3,5-Triazine derivatives and their analogues, pharmaceutical compositions containing same, use thereof as medicine and methods for preparing same - The invention relates to novel derivatives capable of increasing the synthesis and/or the release of neurotrophic factors, and therefore able to be used as a human or veterinary medicinal product. The invention also relates to methods for preparing the derivatives and also to the intermediates required for their synthesis. | 2009-04-23 |
20090105262 | Bridged polycyclic compound based compositions for coating oral surfaces in humans - A pharmaceutically active agent, a pharmaceutically active agent carrier and method of use thereof are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups, and at least two pharmaceutically active agents may be associated with the bridged polycyclic compound. In some embodiments, one or more bridged polycyclic compounds may be applied to an oral surface of a human such that an oral malady may be inhibited and/or ameliorated. | 2009-04-23 |
20090105263 | HETEROBICYCLIC COMPOUNDS AS GLUCOKINASE ACTIVATORS - Compounds of Formula (I): | 2009-04-23 |